While EML4-ALK mRNA can be detected only in the tumor tissues biopsies from non-small-cell lung cancer (NSCLC) patients, detection of F-circEA in plasma of those patients may serve as a potential indicator of EML4-ALK-positive NSCLC and may guide specific EML4-ALK-targeted therapy [20]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.